PDF) Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I)
AEGIS II Design AHA
Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome | JACC: Heart Failure
Investigator-initiated trials of targeted oncology agents: why independent research is at risk? - Annals of Oncology
PDF) Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo- controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects
MegaTrials (> 5,000 patients) - DCRI
![figures_fig1]Study design and timeline.FMC, first medical contact. | Download Scientific Diagram](https://www.researchgate.net/publication/346206981/figure/fig2/AS:961661917741057@1606289476103/figures-fig1Study-design-and-timelineFMC-first-medical-contact.jpg "figures_fig1]Study design and timeline.FMC, first medical contact. | Download Scientific Diagram")
figures_fig1]Study design and timeline.FMC, first medical contact. | Download Scientific Diagram
Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel | Journal of the American College of Cardiology
![PDF] Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5ada797ec2f0c65e74ae75f162e1fcc1ce4a86d4/4-Figure1-1.png "PDF] Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial | Semantic Scholar")
PDF] Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial | Semantic Scholar
Elizabeth Medenilla Clinical Trials and Research Studies of New Treatments - University of Pennsylvania (UPenn)
Update on HDL Infusions and Atherosclerosis Regression in
Entos to commence Phase II Covid-19 vaccine trial in South Africa
.jpg "CSL Behring Announces First Patient Enrollment in Phase 3 Clinical Trial of CSL112 to Assess Reduction of Early Recurrent Cardiovascular Events in Heart Attack Survivors"){kind=logo}
CSL Behring Announces First Patient Enrollment in Phase 3 Clinical Trial of CSL112 to Assess Reduction of Early Recurrent Cardiovascular Events in Heart Attack Survivors
Update on HDL Infusions and Atherosclerosis Regression in
AEGIS II | Valley Health System
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II ( AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo- controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after
Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A‐I and cholesterol efflux capacity in acute myocardial infarction patients - Zheng - 2021 - British Journal of Clinical Pharmacology - Wiley Online Library
Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH ...
CSL Behring Announces First Patient Enrollment in Phase 3 Clinical Trial of CSL112 to Assess Reduction of Early Recurrent Cardiovascular Events in Heart Attack Survivors
Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A‐I and cholesterol efflux capacity in acute myocardial infarction patients - Zheng - 2021 - British Journal of Clinical Pharmacology - Wiley Online Library
CMSJ :: CardioMetabolic Syndrome Journal
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction | Circulation
M. Khurram Afzal MD on Twitter: "AEGIS-II Trial European Investigator Meeting #aegis2trial Not all that complicated! @CMichaelGibson https://t.co/cDkBXs0gHS" / Twitter
Apostolos Dimos MD, MSc - AEGIS-II Trial (NCT03473223) Sub-Investigator - General University Hospital of Larissa | LinkedIn
